Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

BUY

Pharma: The trend is really looking quite good. Hasn’t looked at Merck in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.

PAST TOP PICK

(A TOP PICK Feb 17/11. Up 21.17%.) Still likes but doesn't see as much upside this year.

BUY

An attractive buy. He prefers Abbott Labs (ABT-N), which has growing earnings and is diversified into other products such as medical devices, pharmaceuticals and nutritionals. Terrific dividend. Starting to get attention from value investors.

DON'T BUY

Bit of a poster boy for the whole pharma industry. Something like a leaky boat in that you are rowing and making progress, but constantly bailing. Because of patent expiration, it is very difficult for these companies to create a growth profile.

COMMENT

Has started buying into this sector on the ones that are trading at 10X multiples.

TOP PICK

Model price is $50.75, a 40% upside. Came up 8%-10% in the last couple of weeks, but still has a long ways to go. 4.2% dividend.

TOP PICK

Market was very disappointed in their earnings. Trading at less than 9X earnings. Yield of 4.61%. The model price is $50.15, a 52% upside. It is now all about cost control with these companies. There is huge consolidation in the industry.

WAIT

Recently dropped because they dropped trials of a blood thinner, one of the biggest products in their pipeline. He doesn’t know if this means there will be no sales from this product. He would look seriously at it if it based out at this level. He likes this one and it is reasonable at these levels. He has a small position and is looking to accumulate.

DON'T BUY

Trades at a good multiple but prefers Abbott Labs (ABT-N) because of their pipeline. Growth estimates are only 6%-7% a year.

DON'T BUY

Fine company and reasonably valued but not as cheap as others that he owns. Decent dividend but not anything he would rush into. Still a little uncertainty over the healthcare sector and particularly with this one's pipeline area. Consider Abbott Labs (ABT-N), which has more growth potential.

COMMENT

Took over Schering-Plough in 2009, which expanded their pipeline of pharmaceuticals, drugs, etc. Pays about 4% yield so likes it from an income standpoint. With a 40% payout ratio dividend is relatively safe. Might not give you growth that you would like. If you think economy is going to grind higher, health care is not a sector to be in.

PAST TOP PICK

(A Top Pick Aug 19/09. Up 15.9%.) Merged with Schering-Plough and the combination produced a pipeline that is incomparable in the Pharma sector. Will have sustainable growth for many years to come.

PAST TOP PICK

(A Top Pick May 15/09. Up 46.13%.) (Think this should be Aug 19 and up 12.2%, not May 15 as BNN shows. Bill) Starting to trim out of this one.

DON'T BUY

3rd largest pharmaceutical behind Johnson & Johnson (JNJ-N) and Pfizer (PFE-N). We are in an economic recovery and if this continues and there is no double dip, health-care stocks and consumer staples won't necessarily be your best performers.

DON'T BUY

Pfizer (PFE-N) and Merck (MRK-N) are pretty fully priced at current levels. Growth prospects are not that great, especially with a lot of drugs coming off patent. Multiple looks attractive and dividend looks okay but there are better places to go in pharmaceuticals. Prefers Abbott Labs (ABT-N).

Showing 196 to 210 of 304 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)